Terns Pharmaceuticals, Inc. (TERN)
Dopo ore:
| Chiusura precedente | 5,61 |
| Aperto | 5,90 |
| Denaro | 3,78 x 1800 |
| Lettera | 6,35 x 1100 |
| Min-Max giorno | 5,66 - 6,14 |
| Intervallo di 52 settimane | 1,45 - 7,92 |
| Volume | |
| Media Volume | 185.531 |
| Capitalizzazione | 229,642M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,01 |
| Prossima data utili | 09 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,00 |
- GlobeNewswire
Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
Terns plans to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023Positive data from Phase 1 trial of TERN-501 (THR-β agonist) in NASH presented at AASLD 2022, with top-line data from Phase 2a DUET trial expected in second half of 2023IND-enabling activities for TERN-601 (oral GLP-1R agonist) remain on track with plans to initiate first-in-human clinical trial in obesity in 2023Cash and equivalents of $187 million provides runway into 2025, incl
- GlobeNewswire
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy Phase 2a DUET trial evaluating TERN-501 alone and in combination with TERN-101, the first trial assessing both THR-β and FXR agonists in NASH, is ongoing FOSTER CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company
- GlobeNewswire
Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022
FOSTER CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that the company will present two abstracts regarding its investigational therapies TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, in clinical dev
